Tema Etfs LLC Buys Shares of 3,846 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Tema Etfs LLC acquired a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 3,846 shares of the company's stock, valued at approximately $525,000.

Several other large investors also recently added to or reduced their stakes in the business. Golden State Wealth Management LLC bought a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at about $25,000. Huntington National Bank increased its position in shares of Neurocrine Biosciences by 73.5% in the fourth quarter. Huntington National Bank now owns 229 shares of the company's stock worth $31,000 after purchasing an additional 97 shares during the last quarter. Brooklyn Investment Group raised its stake in Neurocrine Biosciences by 99.1% in the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company's stock valued at $32,000 after purchasing an additional 115 shares in the last quarter. GeoWealth Management LLC lifted its position in Neurocrine Biosciences by 65.4% during the fourth quarter. GeoWealth Management LLC now owns 258 shares of the company's stock valued at $35,000 after purchasing an additional 102 shares during the last quarter. Finally, Lindbrook Capital LLC grew its stake in Neurocrine Biosciences by 53.5% in the 4th quarter. Lindbrook Capital LLC now owns 373 shares of the company's stock worth $51,000 after buying an additional 130 shares in the last quarter. Institutional investors own 92.59% of the company's stock.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director William H. Rastetter sold 30,000 shares of the stock in a transaction on Monday, May 5th. The stock was sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the sale, the director now directly owns 37,491 shares in the company, valued at approximately $4,131,508.20. This trade represents a 44.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

NBIX has been the subject of a number of research analyst reports. Evercore ISI dropped their price objective on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. UBS Group lifted their price target on Neurocrine Biosciences from $137.00 to $152.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. William Blair reiterated an "outperform" rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Wedbush reissued an "outperform" rating on shares of Neurocrine Biosciences in a report on Tuesday, May 6th. Finally, StockNews.com lowered Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research note on Thursday, March 20th. Three research analysts have rated the stock with a hold rating and twenty have given a buy rating to the stock. Based on data from MarketBeat.com, Neurocrine Biosciences presently has an average rating of "Moderate Buy" and a consensus price target of $162.00.

Neurocrine Biosciences Stock Down 2.0%

Shares of NBIX traded down $2.40 during mid-day trading on Wednesday, hitting $120.56. 964,821 shares of the company's stock traded hands, compared to its average volume of 1,133,533. The business's 50-day moving average price is $107.58 and its 200-day moving average price is $121.94. The firm has a market capitalization of $11.93 billion, a P/E ratio of 36.64, a PEG ratio of 0.77 and a beta of 0.26. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. The business had revenue of $572.60 million for the quarter, compared to the consensus estimate of $587.06 million. During the same quarter last year, the firm posted $1.20 EPS. The business's quarterly revenue was up 11.1% on a year-over-year basis. Sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Neurocrine Biosciences announced that its Board of Directors has initiated a share repurchase plan on Friday, February 21st that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 4.2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's leadership believes its stock is undervalued.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.